Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica

被引:62
|
作者
Narvaez, Javier [1 ]
Estrada, Paula [1 ]
Lopez-Vives, Laura [1 ]
Ricse, Milagros [1 ]
Zacarias, Andrea [1 ]
Heredia, Sergi
Gomez-Vaquero, Carmen [1 ]
Nolla, Joan M. [1 ]
机构
[1] Hosp Univ Bellvitge IDIBELL, Dept Rheumatol Planta 10 2, Feixa Llarga S-N, Barcelona, Spain
关键词
Giant cell arteritis; Polymyalgia rheumatica; Ischemic complications; TERM FOLLOW-UP; TEMPORAL ARTERITIS; DUPLEX ULTRASONOGRAPHY; DIAGNOSIS; EPIDEMIOLOGY; PATHOGENESIS; INVOLVEMENT; FEATURES; THERAPY; SERIES;
D O I
10.1016/j.semarthrit.2015.06.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate the frequency and type of giant cell attends (GCA)-related ischemic complications in a series of patients with GCA who, for a substantial period of time (i.e., at least 3 mo), lacked vascular symptoms and presented with apparently isolated polymyalgia rheumatica (PMR). Methods: Retrospective follow-up study of an unselected population of 167 patients with GCA diagnosed from 1985 to 2014. Results: In all, 18 patients (11%) developed GCA on a background of a prior history of PMR. They were diagnosed as having isolated PMR because they did not have clinical evidence of GCA at diagnosis and exhibited a prompt and complete response to low-dose steroid therapy. However, during the course of treatment. 17 patients later experienced an arteritic relapse with the development of typical craniofacial symptoms, and one patient developed signs of upper extremity vascular insufficiency, resulting in the diagnosis of large-vessel GCA. The median time to GCA diagnosis from the initiation of low-dose steroid therapy was 9 14.4 mo (range: 3-39). At the time of GCA diagnosis, severe ischemic complications were observed in 50% (9/18) of the patients. Of these patients 22% (4/18) were considered to have "true" occlusive disease (i.e., permanent visual loss, stroke, and/or limb claudication). Late inflammation of the aorta and its branches occurred in 4 (22%) of the patients during long-term follow-up. Conclusion: Patients with GCA presenting with apparently isolated PMR have a significant risk of developing transient or permanent disease -related ischemic complications; these complications occurred in 50% of the cases. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:328 / 333
页数:6
相关论文
共 50 条
  • [31] Unmet need in the treatment of polymyalgia rheumatica and giant cell arteritis
    Sun, Margaret Man-Ger
    Pope, Janet E.
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2022, 36 (04):
  • [32] Polymyalgia Rheumatica, Temporal Arteritis, Giant Cell Arteritis: Definitions and Epidemiological Data
    Keysser, G.
    AKTUELLE RHEUMATOLOGIE, 2014, 39 (04) : 220 - 222
  • [33] Primary Care Vasculitis Polymyalgia Rheumatica and Giant Cell Arteritis
    Pioro, Mathilde H.
    PRIMARY CARE, 2018, 45 (02): : 305 - +
  • [34] Lower extremity vasculitis in polymyalgia rheumatica and giant cell arteritis
    Kermani, Tanaz A.
    Warrington, Kenneth J.
    CURRENT OPINION IN RHEUMATOLOGY, 2011, 23 (01) : 38 - 42
  • [35] The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population
    Yates, Max
    Graham, Karly
    Watts, Richard Arthur
    MacGregor, Alexander James
    BMC MUSCULOSKELETAL DISORDERS, 2016, 17
  • [36] Recognition of giant cell arteritis in patients with polymyalgia rheumatica who have a stroke: a cautionary tale
    Gutteridge, Donald H.
    Mastaglia, Frank L.
    INTERNAL MEDICINE JOURNAL, 2017, 47 (10) : 1199 - 1201
  • [37] Giant cell arteritis and polymyalgia rheumatica: Role of cytokines in the pathogenesis and implications for treatment
    Manuel Martinez-Taboada, Victor
    Alvarez, Lorena
    RuizSoto, Maria
    Jose Marin-Vidalled, Maria
    Lopez-Hoyos, Marcos
    CYTOKINE, 2008, 44 (02) : 207 - 220
  • [38] Plasma adrenomedullin levels in patients with polymyalgia rheumatica and giant cell arteritis
    Garcia-Unzueta, M. T.
    Martinez-Taboada, V. M.
    Amado, J. A. Senaris
    Rodriguez-Valverde, V.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2006, 24 (02) : S6 - S9
  • [39] Genetic epidemiology Giant cell arteritis and polymyalgia rheumatica
    Gonzalez-Gay, MA
    ARTHRITIS RESEARCH, 2001, 3 (03) : 154 - 157
  • [40] Optimal management of giant cell arteritis and polymyalgia rheumatica
    Charlton, Rodger
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2012, 8 : 173 - 179